Pictilisib (GDC-0941)

Catalog No.S1065

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pictilisib (GDC-0941) Chemical Structure

Pictilisib (GDC-0941) Chemical Structure
Molecular Weight: 513.64

Validation & Quality Control

Cited by 57 publications:

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Pictilisib (GDC-0941) is available in the following compound libraries:

PI3K Inhibitors with Unique Features

  • Pan PI3K Inhibitor

    LY294002 Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.

  • Most Potent PI3K Inhibitor

    Duvelisib (IPI-145, INK1197) PI3K δ, IC50=1 nM.

  • FDA-approved PI3K Inhibitor

    CAL-101 (Idelalisib, GS-1101) Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.

  • Newest PI3K Inhibitor

    GSK2636771 Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Product Information

  • Compare PI3K
    Compare PI3K Products
  • Research Area
  • Inhibition Profile
  • Pictilisib (GDC-0941) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Targets p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)

 View  More

IC50 3 nM 3 nM 33 nM 75 nM
In vitro GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. [1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. [2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. [3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Sf9NUDiWo5FU2mwYYPlJGF{e2G7NIXyS3EyKGh?NXHIUHY4TE2VTx?=Moi5TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHPv[ZhxemW|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh|ryPMlPYNVg4PTR4NUS=
Sf9M3uzUmtqdmG|ZTDBd5NigQ>?M{G2NlEhcA>?MmHoSG1UVw>?NIjHdGRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhUDFyNEetVkBufXSjboSg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?MWexPFc2PDZ3NB?=
Sf9MoLzT4lv[XOnIFHzd4F6MVKxJIg>MmLHSG1UVw>?NEHpeXNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhTTV2NT3LJI12fGGwdDDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGOxZYjwdoV{e2mwZzDwPFVidHCqYTD3bZRpKEmFNUCgc4YhOC5yMEOg{txOMkPoNVg4PTR4NUS=
Sf9MmHuT4lv[XOnIFHzd4F6NIC0bWgyKGh?M3HEd2ROW09?NYnLbolMUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=NF;GR24yQDd3NE[1OC=>
Sf9MlfKT4lv[XOnIFHzd4F6MknPNUBpMYHEUXNQMXHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO|aX7nJJA5PWGucHjhMUWxPFc2PDZ3NB?=
MDA-MB-361MlG3SpVv[3Srb36gRZN{[Xl?MUSyJIg>NH\iUZhFVVORNFHxcXRKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1|NkGgZ4VtdHNid3n0bEBRUUt|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{ODFOwG0>MXKxPFc2PDZ3NB?=
PC3MlOwSpVv[3Srb36gRZN{[Xl?NUXJOHF4OiCqMl3JSG1UVw>?MWrJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODN5IN88US=>MWKxPFc2PDZ3NB?=
U87MGNInN[pNHfW6ldHnvckBCe3OjeR?=Mn\XNkBpM2X3TmROW09?NIDjU3lKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh|ryPMUmxPFc2PDZ3NB?=
MDA-MB-361MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETzPHI6PiCqMWfEUXNQM4DDTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvPzJizszNMUCxPFc2PDZ3NB?=
A2780NIjDdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV65OkBpNIDRSFZFVVORMoDvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDMke4NEBk\WyuczD3bZRpKFCLS{PDRUBidmRiUGTFUkBufXSjdHnvckB4cXSqIFnDOVAhd2ZiMD6xOEDPxE1?MUOxPFc2PDZ3NB?=
PC3NFzYNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFqyV2U6PiCqMX\EUXNQNG\LN4ZKSzVyPUCuNlgh|ryPMVexPFc2PDZ3NB?=
U87MGMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULsPI0zQTZiaB?=MX\EUXNQMmDvTWM2OD1yLkm1JO69VQ>?M3;qcVE5PzV2NkW0
Sf9NGjXbIJMcW6jc3WgRZN{[Xl?M3rie|MxKG2rbh?=NXzTTFI6TE2VTx?=MVXJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiYX3veY51KG:oIFHUVEBkd26|dX3l[EB4cXSqIFnDOVAhd2ZiMD6wOFIh|ryPNGG0cW8zOjV2OEO0Ni=>
RAW 264.7NWTQTmlZU2mwYYPlJGF{e2G7M1nkcVkxKG2rbh?=M{j3fGROW09?M2DPfmlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvOjl6IN88US=>NILKc4EzOjV2OEO0Ni=>
Sf9Mn3FT4lv[XOnIFHzd4F6NHjubo8yKGh?M2XXOmlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVRkmgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODF5IN88US=>M1\NWlI{PTRyNkS1
Sf9MXHLbY5ie2ViQYPzZZk>M{HN[lEhcA>?NGrxVYhKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\GWudHGg[ZhxemW|c3XkMXKyN|U1ODZ2NR?=
Sf9MmHhT4lv[XOnIFHzd4F6NVvvXZhPOSCqNVi3eZNCUW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>NFvPfmQzOzV2ME[0OS=>
Sf9NYjiNW11U2mwYYPlJGF{e2G7MYmxJIg>MX3Jcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2WmMnS0NlM2PDB4NEW=
SKOV3NEXHN2VMcW6jc3WgRZN{[Xl?MX[xJO69VQ>?MV2xJIg>MWrEUXNQMYnJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vMVKyN|M3ODN2OB?=
MCF7Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYexJO69VQ>?Mn31PVYhcA>?NVTYfG1vTE2VTx?=MYHHTVUxRTBwMEewNkDPxE1?NH:xSXYzOzN4MEO0PC=>
SKOV3MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n6NFEh|ryPM3f0T|k3KGh?MnTrSG1UVw>?MmH4S2k2OD1yLkG0O|Yh|ryPMXqyN|M3ODN2OB?=
PC3NX\1SGx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fUOFczKGh?NGjwSIhFVVORMV\JR|UxRTBwMkig{txOMV[yNVk5OTdzNB?=
MCF7.1M3zoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nGTlczKGh?MX7EUXNQM17lWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochUEWUMjDn[Y5mKHerdHigTWM2OCCxZjCwMlI5KM7:TR?=M3TyWlIyQThzN{G0
MCF7-neo/Her2M4fvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXvVGE4OiCqNF7KPHZFVVORMUTJR|UxRTBwMkmg{txOMV2yN|Y3OjlyMx?=
MCF7-neo/Her2MoDZT4lv[XOnIFHzd4F6NUHhOnNmUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txOMn[0NlM3PjJ7MEO=
PC3M2HXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU[3NkBpNIPrZplFVVORMmG0SWM2OD1yLkO0JO69VQ>?MnTxNlE6QDV4M{m=
MCF7.1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXm4coU2PzJiaB?=MnnzSG1UVw>?NELSXplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDFR|UxKG:oIECuN|kh|ryPMkHGNlE6QDV4M{m=
PC3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV23NkBpMnjtSG1UVw>?MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCmZX\pZ4lmdnRiaX6gVHRGViC5aYToJGlEPTBib3[gNE4{QSEQvF2=MW[yNFA2ODZ4OR?=
MCF7.1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzSSHc4OiCqNGPsVmlFVVORNVXNOYE4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFibYX0ZY51KHerdHigTWM2OCCxZjCwMlM1KM7:TR?=MW[yNFA2ODZ4OR?=
MCF7.1NFPLfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHSO|IhcA>?NIftOW5GSzVyPUCuO|Ih|ryPM1r2elIxOzR4NkW2
NCI-H1975MmX1R5l1d3SxeHnjJGF{e2G7MV[3NkBpMYPJR|UxRTBwMkeg{txOMn7JNlMxPTl3NEW=
H460NF7ybIZEgXSxdH;4bYMhSXO|YYm=M2L6e|czKGh?MWrJR|UxRTBwOEeg{txOM3rDO|I{ODV7NUS1
HT-29NFyyc4hEgXSxdH;4bYMhSXO|YYm=NWLY[lVzPzJiaB?=MYfJR|UxRTBwNk[g{txONY\sPJU1OjNyNUm1OFU>
HepG2MW\DfZRwfG:6aXOgRZN{[Xl?MUe3NkBpNYXNZmFjUUN3ME2xJO69VQ>?MmH6NlMxPTl3NEW=
SGC7901MUjDfZRwfG:6aXOgRZN{[Xl?M{\vblczKGh?NIHNS3dKSzVyPUGuPEDPxE1?M2HvRlI{ODV7NUS1
NCI-H226NYn1VJB3S3m2b4TvfIlkKEG|c3H5NHzMXpU4OiCqMVXJR|UxRTJwOTFOwG0>NV[wWoVGOjNyNUm1OFU>
A549M3\SSWN6fG:2b4jpZ{BCe3OjeR?=MUC3NkBpMmPLTWM2OD14Lkmg{txOM17YUVI{ODV7NUS1
U87MGMoDiR5l1d3SxeHnjJGF{e2G7M4TkOVczKGh?NIXGd4VKSzVyPUeuO|ch|ryPMV2yN|A2QTV2NR?=
HBC4NFfxdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzpXoFEdG:pR1m1NF0uPi5yMzDNMWOyNlM{PjJ2Nh?=
BSY1M2DsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrBXmN[dG:pR1m1NF0uPi57MDDNNXXqSVdHOjJ|M{[yOFY>
HBC5NYHCSnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPBfnptd2eJSUWwQU03NjZyIF2=NIfzXlczOjN|NkK0Oi=>
MCF7NH\CcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4WyNYxw\0eLNUC9MVcvOzNiTR?=M1PNSVIzOzN4MkS2
MDA-MB-231NFPWOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[zcI9oT0l3ME2tOU41PiCPNG[zW|czOjN|NkK0Oi=>
U251NWfRXY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7yOlVtd2eJSUWwQU02NjVyIF2=NGrkb4QzOjN|NkK0Oi=>
SF268NYLN[XhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\sc4dIUTVyPT21MlM6KE1?NEK3bGkzOjN|NkK0Oi=>
SF295MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrsc4dIUTVyPT22MlM4KE1?MWeyNlM{PjJ2Nh?=
SF539MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPBOFBPdG:pR1m1NF0uPi53MDDNMmC2NlI{OzZ{NE[=
SNB75NHPNPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS2UHNtd2eJSUWwQU04NjFyIF2=MVmyNlM{PjJ2Nh?=
SNB78MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTielFGdG:pR1m1NF0uPi53MjDNNYOwNGhXOjJ|M{[yOFY>
HCC2998NX71NoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPXd2lxdG:pR1m1NF0uPi5{OTDNM2\OVFIzOzN4MkS2
KM12MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYP0N4RTdG:pR1m1NF0uPS55NjDNMmfNNlI{OzZ{NE[=
HT-29MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3eycIxw\0eLNUC9MVYvOzBiTR?=NWnWWpc1OjJ|M{[yOFY>
HCT15MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLxcI9oT0l3ME2tOk4yOiCPM13BWlIzOzN4MkS2
HCT116Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXEXoltd2eJSUWwQU02Njh5IF2=NWHNepJ5OjJ|M{[yOFY>
NCI-H23MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIG0Tmdtd2eJSUWwQU02Njd|IF2=M1HGOVIzOzN4MkS2
NCI-H226Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\sc4dIUTVyPT22MlIyKE1?NGnnPI0zOjN|NkK0Oi=>
NCI-H522NIf6RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrnOnhydG:pR1m1NF0uPi53ODDNNGXSO4wzOjN|NkK0Oi=>
NCI-H483MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULsc4dIUTVyPT22MlU3KE1?MlnJNlI{OzZ{NE[=
A549MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDycI9oT0l3ME2tOk4yPSCPM4\2W|IzOzN4MkS2
DMS273MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnCWJJUdG:pR1m1NF0uPi52MzDNNFzsdoQzOjN|NkK0Oi=>
DMS114NWLhUYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV:5d25kdG:pR1m1NF0uPS57MjDNNF3TcFIzOjN|NkK0Oi=>
LOXIMVINWLjT5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T0TIxw\0eLNUC9MVYvOjliTR?=NHi3RlMzOjN|NkK0Oi=>
OVCAR3NUCwOXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfTfm1td2eJSUWwQU03NjdzIF2=NUn2RWdxOjJ|M{[yOFY>
OVCAR4M2jWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\wS5J3dG:pR1m1NF0uPS55NjDNNFPjSZozOjN|NkK0Oi=>
OVCAR5NF;sPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnqcGRxdG:pR1m1NF0uPi5{NjDNNETwWFgzOjN|NkK0Oi=>
OVCAR8NEWwSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S1[oxw\0eLNUC9MVUvPzNiTR?=M2LyS|IzOzN4MkS2
SKOV3NHTNc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnsc4dIUTVyPT22MlUzKE1?MYKyNlM{PjJ2Nh?=
RXF631LM4rTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIS1UXptd2eJSUWwQU03Njh6IF2=NUjkeYhJOjJ|M{[yOFY>
ACHNNVnnVVliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\jXoxw\0eLNUC9MVYvODdiTR?=MofNNlI{OzZ{NE[=
St-4NX;jVoI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvDUHBtd2eJSUWwQU02NjV4IF2=M2DpSFIzOzN4MkS2
MKN1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjScI9oT0l3ME2tO{4xQCCPMmmxNlI{OzZ{NE[=
MKN7MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnsc4dIUTVyPT22MlUxKE1?NETzZo8zOjN|NkK0Oi=>
MKN28NV33[GVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLsc4dIUTVyPT21MlUzKE1?M{\EOlIzOzN4MkS2
MKN45NGCzS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIC3[m9td2eJSUWwQU03NjV3IF2=MUWyNlM{PjJ2Nh?=
MKN74M3flN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoC5cI9oT0l3ME2tOk4xOiCPMUKyNlM{PjJ2Nh?=
DU145NHTkXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXTZXpmdG:pR1m1NF0uPS56NTDNMYqyNlM{PjJ2Nh?=
PC3MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PXSoxw\0eLNUC9MVYvPjZiTR?=NF\YSZozOjN|NkK0Oi=>
ES5NYLRXlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLqTWM2OD13MD6yNUBvVQ>?NYrYeGw3W0GQR1XS
HHMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jsT2lEPTB;MUGxMlA5KG6PMVXTRW5ITVJ?
MHH-PREB-1M2\EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fTdWlEPTB;MUG0MlMhdk1?MnXOV2FPT0WU
NCI-H1770MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDMTWZKSzVyPUGyN{45PiCwTR?=MWTTRW5ITVJ?
HuO9NXLKcFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17hUmlEPTB;MkC2MlAzKG6PNXvZc3hQW0GQR1XS
HAL-01NGPGVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrCNZdKSzVyPUKwOk44OyCwTR?=NG\JfmtUSU6JRWK=
NOS-1M1\Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTJzMT64NkBvVQ>?MYHTRW5ITVJ?
HGC-27M3Ptc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvKSI1KSzVyPUKxNk42PyCwTR?=MmjiV2FPT0WU
NB69MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmflTWM2OD1{NEWuNlchdk1?MWLTRW5ITVJ?
RS4-11MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfRb5luUUN3ME2yOlEvPzZibl2=MnHJV2FPT0WU
DOKMlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfmTWM2OD1|MEGuO{BvVQ>?NXTWWpA2W0GQR1XS
LB2241-RCCM4\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T6VmlEPTB;M{CzMlg1KG6PNEGze2NUSU6JRWK=
NCI-H1623NXz1fHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLnTWM2OD1|MESuNFghdk1?M3XsOHNCVkeHUh?=
YH-13MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LBfmlEPTB;M{C0MlMzKG6PNIWzOoxUSU6JRWK=
BPH-1NFjGRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTLXpF1UUN3ME2zNVQhdk1?M2qzdnNCVkeHUh?=
AN3-CAMnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoizTWM2OD1|NECuN|chdk1?MWXTRW5ITVJ?
ES7NVSxe|hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkftTWM2OD1|NEGuPVkhdk1?MVnTRW5ITVJ?
MDA-MB-175-VIINXnjWpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLOeIpKSzVyPUO1Nk46OiCwTR?=M4fpSHNCVkeHUh?=
GAMGMnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TlVWlEPTB;M{ewMlg2KG6PNH34dHRUSU6JRWK=
CHL-1NHrPd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HaRmlEPTB;M{e4MlY2KG6PM3f0eHNCVkeHUh?=
NB7NVnZbXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLRTWM2OD1|OEmuPFMhdk1?NGrncIFUSU6JRWK=
MFE-280MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXv1VJBrUUN3ME20NVgvOiCwTR?=M1m1THNCVkeHUh?=
HL-60NEeyTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEX0XmFKSzVyPUSyOU44PSCwTR?=MWHTRW5ITVJ?
GCIYMn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR|Mz64JI5ONX7JfY9IW0GQR1XS
MDA-MB-361NETiVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTR|OT6xN{BvVQ>?MYDTRW5ITVJ?
LXF-289NYHDVVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXDfotKSzVyPUS0PE4zPyCwTR?=MX\TRW5ITVJ?
NBsusSRMnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH6TWM2OD12OEiuPFUhdk1?NXLqO4k4W0GQR1XS
KU-19-19MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1f0SWlEPTB;NUG2MlA4KG6PNFvPWW9USU6JRWK=
A204MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\TcZNKSzVyPUWyNk4{OyCwTR?=M37DcHNCVkeHUh?=
LB1047-RCCMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTV{Mj65N{BvVQ>?M2\wZ3NCVkeHUh?=
COLO-684M37hc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPPZmdKSzVyPUWyN{4yOSCwTR?=NFWyU3hUSU6JRWK=
PA-1NFLyXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTV|Mj60NUBvVQ>?M1XvNHNCVkeHUh?=
MG-63MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn6TIhKSzVyPUW0NU4yOSCwTR?=NVq4N5JzW0GQR1XS
BHT-101M37nXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuxVJdKSzVyPUW0OE46PCCwTR?=M3XJRXNCVkeHUh?=
NKM-1MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPmZo9KSzVyPUW5N{4xQSCwTR?=NFPZXJBUSU6JRWK=
T47DM2TUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjOTWM2OD13OUeuOVYhdk1?M2D6NHNCVkeHUh?=
MOLT-4M4f5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW3TWM2OD14MkOuOlIhdk1?NX;hWXlvW0GQR1XS
IGROV-1M{DnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTZ|ND6zNUBvVQ>?MULTRW5ITVJ?
ES4M4r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTZ|OT61OEBvVQ>?NV3y[GI{W0GQR1XS
HuO-3N1NWXzNZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzwTWM2OD14NEKuN|ghdk1?MV7TRW5ITVJ?
NEC8NHP2OoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTZ3Mz61O{BvVQ>?MYfTRW5ITVJ?
HO-1-N-1NH\xW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnT1TWM2OD14NUmuNVchdk1?MWnTRW5ITVJ?
EPCL-272HM2Xxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTZ6Nz6yNUBvVQ>?MV;TRW5ITVJ?
D-263MGMkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnH1TWM2OD15MUiuNUBvVQ>?NHGzfZNUSU6JRWK=
MV-4-11Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPKcZUzUUN3ME23NlQvOzFibl2=MkTWV2FPT0WU
SK-NEP-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHkW3ZpUUN3ME23NlUvQTRibl2=M{LHfHNCVkeHUh?=
SW872Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jVUWlEPTB;N{K3Mlg6KG6PMUTTRW5ITVJ?
P30-OHKMnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnITWM2OD15M{CuO|Ehdk1?NGPuUWJUSU6JRWK=
OMC-1NHq2WJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXNb5JvUUN3ME23OVEvODlibl2=M2K3SHNCVkeHUh?=
LoVoMmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGK2[nVKSzVyPUe3O{46KG6PNYfvNnVYW0GQR1XS
LNCaP-Clone-FGCNEj3NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TxO2lEPTB;N{m2MlM1KG6PNFHrNXRUSU6JRWK=
L-363MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTd7OD60NkBvVQ>?NFHxcVlUSU6JRWK=
ES8MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRThzMD61NkBvVQ>?M2C4VXNCVkeHUh?=
697MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXkTWM2OD16M{GuOVUhdk1?Mle5V2FPT0WU
HSC-3M4rte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTh|OT61OEBvVQ>?NV25dGNwW0GQR1XS
H4M2HCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoCxTWM2OD16NUCuPFUhdk1?MlzJV2FPT0WU
QIMR-WILNXnlcnZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XpdWlEPTB;OE[1MlIhdk1?NWD2NI5RW0GQR1XS
OAW-42M1PHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17jUmlEPTB;OEeyMlE6KG6PMV;TRW5ITVJ?
MCF7M3nQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\V[WlEPTB;OEm4MlU6KG6PMmrlV2FPT0WU
SCC-25MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWn0R29rUUN3ME25NVQvOTlibl2=NHrheJdUSU6JRWK=
NCI-H1563MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTlzNT65PUBvVQ>?MkDEV2FPT0WU
OVCAR-5NGXKeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTl2MD6xO{BvVQ>?MlzCV2FPT0WU
HDLM-2NXzsT2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PwOWlEPTB;OUS5MlIhdk1?M2rpRnNCVkeHUh?=
NB5MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml61TWM2OD17NU[uOkBvVQ>?M1K5TnNCVkeHUh?=
NCI-H292M2myfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{j1UmlEPTB;OUe0MlMzKG6PNVqyOWVPW0GQR1XS
A101DNV3BR2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTl7MD6xPUBvVQ>?MlraV2FPT0WU
NCI-H1648MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjMT4VDUUN3ME25PVgvPTFibl2=NHXaOXlUSU6JRWK=
EKVXMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrEUGxmUUN3ME2xMlAyOjlizszNMnzqV2FPT0WU
SW1710Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nFV2lEPTB;MT6wOFI{OyEQvF2=M2LVcnNCVkeHUh?=
WM-115MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nuPWlEPTB;MT6wOlY2PiEQvF2=MULTRW5ITVJ?
CAL-54MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFwMEewPFEh|ryPNF\4eZBUSU6JRWK=
TGBC24TKBM2CwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzTc5VKSzVyPUGuNFgxPDVizszNNIryUZRUSU6JRWK=
NCI-H520MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2qyfWlEPTB;MT6wPFk3PyEQvF2=NWX1eWloW0GQR1XS
D-423MGNELjfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\2blFKSzVyPUGuNFk6PjJizszNMYjTRW5ITVJ?
BFTC-905NYHnU4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTaTWM2OD1zLkGzOFQ6KM7:TR?=M4HUXnNCVkeHUh?=
HTMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTa[VZKSzVyPUGuNVM1PzhizszNNHSwb5RUSU6JRWK=
CTB-1NV\2cYJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nNNGlEPTB;MT6xOFI6OyEQvF2=NFPxNIdUSU6JRWK=
Hs-578-TMnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnKV3VKSzVyPUGuNVk2PjVizszNNIr4XopUSU6JRWK=
HuH-7NGK3S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFwMkC5OFkh|ryPMonEV2FPT0WU
LB996-RCCNEOxW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjmc4RKUUN3ME2xMlIzOTd5IN88US=>NV33OmQ{W0GQR1XS
KYSE-270M1fydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTFwMkm3N|Qh|ryPNWTuT|NUW0GQR1XS
A4-FukMkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDCTWM2OD1zLkK5PVk{KM7:TR?=M37iN3NCVkeHUh?=
A498MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlP1TWM2OD1zLkOwOFc1KM7:TR?=NXGwPIVUW0GQR1XS
SK-MEL-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\3eFVKSzVyPUGuN|A3PzlizszNM3uzR3NCVkeHUh?=
AU565NYfCPYhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLDZnVWUUN3ME2xMlMyQDZ|IN88US=>MYHTRW5ITVJ?
Saos-2MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXe5SlZOUUN3ME2xMlM{OjB3IN88US=>NWT2eVdpW0GQR1XS
A549MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[z[5VKSzVyPUGuN|k6PyEQvF2=NUXMZWN5W0GQR1XS
BFTC-909MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXlUY1KSzVyPUGuOFM{ODVizszNNF\xfWNUSU6JRWK=
MDA-MB-415NYjyZXhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHuTWM2OD1zLkS4OlkzKM7:TR?=M1;rdXNCVkeHUh?=
639-VM1H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHiZYVjUUN3ME2xMlUxOjR3IN88US=>MkS3V2FPT0WU
A704MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3acWJKSzVyPUGuOVA4QDVizszNMnW0V2FPT0WU
PANC-03-27MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX72fHFbUUN3ME2xMlUyPDB6IN88US=>NGDGUmlUSU6JRWK=
SK-MEL-28M4jL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTFTWM2OD1zLkW2NFg2KM7:TR?=NWfES|VPW0GQR1XS
Ramos-2G6-4C10NUT1N2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nPZ2lEPTB;MT62NFc1PiEQvF2=NFfzOplUSU6JRWK=
HuP-T4NIfSbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LaUmlEPTB;MT62NFc4QCEQvF2=NVT3TnhVW0GQR1XS
VA-ES-BJMkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LhVWlEPTB;MT62NVI4KM7:TR?=NI\TbopUSU6JRWK=
EFM-19MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[zTWM2OD1zLk[xPFEh|ryPM2f4bXNCVkeHUh?=
G-401MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TrR2lEPTB;MT62NlE3PCEQvF2=Ml;wV2FPT0WU
D-566MGMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTFwNkK1N{DPxE1?NGDpOGJUSU6JRWK=
JVM-3MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHwSFdpUUN3ME2xMlY1QDd3IN88US=>NV3Td4o2W0GQR1XS
TK10M1HxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWWyO5hGUUN3ME2xMlY4ODh|IN88US=>NGTWZWpUSU6JRWK=
BT-20MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwNki5NFIh|ryPMkKyV2FPT0WU
EGI-1MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUW1c4RCUUN3ME2xMlg1PzBzIN88US=>MX3TRW5ITVJ?
EW-16MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\hRWlEPTB;MT64OVE5OiEQvF2=M37hZ3NCVkeHUh?=
NCI-H2228NI\4bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfQOIxOUUN3ME2xMlg2OjB|IN88US=>NUPWcnBIW0GQR1XS
BB49-HNCNIjwZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH1TWM2OD1zLki4OlkzKM7:TR?=NW\DUlVUW0GQR1XS
G-402MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfw[IpKSzVyPUGuPFk4QTdizszNMVHTRW5ITVJ?
NCI-H526MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFwOUGzPUDPxE1?MljsV2FPT0WU
ME-180MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fSNmlEPTB;MT65N|Q4PyEQvF2=MYTTRW5ITVJ?
PFSK-1M3LKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDjSWNKSzVyPUGuPVQ1PThizszNNETXZppUSU6JRWK=
TYK-nuMn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHQR5IzUUN3ME2xMlk2QDJ|IN88US=>MXrTRW5ITVJ?
HOSNWfsdpE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXMTWM2OD1zLkm3PVQ5KM7:TR?=M1\w[3NCVkeHUh?=
T98GMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LxN2lEPTB;MT65PVAxPiEQvF2=MUXTRW5ITVJ?
SK-MES-1MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\iTWM2OD1{LkCxN|MzKM7:TR?=NXfxUFBTW0GQR1XS
SNB75NH7ac3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJwMEG1OFEh|ryPM1y1OXNCVkeHUh?=
LAMA-84NGL5TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS0OXcxUUN3ME2yMlAzPjh7IN88US=>MWPTRW5ITVJ?
CAL-39M2S0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJwMEOyPEDPxE1?NF[wVmNUSU6JRWK=
LOXIMVIMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;vXGlEPTB;Mj6wOFA5PCEQvF2=NV60ToJXW0GQR1XS
NH-12NILKZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTJwMEW0NlQh|ryPNHHYOW5USU6JRWK=
NCI-H1048MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\Zdm4{UUN3ME2yMlExPTJizszNMVfTRW5ITVJ?
KS-1NUL3O49xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrP[mFKSzVyPUKuNVExODFizszNM1[5SHNCVkeHUh?=
NCI-N87MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUn0WFZEUUN3ME2yMlE{Ozh2IN88US=>MkTlV2FPT0WU
CHP-212NGr5bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXKXplbUUN3ME2yMlE5PDR{IN88US=>MU\TRW5ITVJ?
HCC1419Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnlWlNKSzVyPUKuNlEyOTVizszNNGWxT3ZUSU6JRWK=
ES1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJwMkGzNlYh|ryPMYHTRW5ITVJ?
NCI-H2030NX3tRodZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTVTWM2OD1{LkK0NVI{KM7:TR?=NUKzclN7W0GQR1XS
EW-22M1;VWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\WW49KSzVyPUKuNlUxPjdizszNNGLX[3FUSU6JRWK=
A431NYXSSWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz6VGVKSzVyPUKuNlc{PTRizszNMYXTRW5ITVJ?
SF126NVj0fYtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HRUGlEPTB;Mj6zNFYzPSEQvF2=MonoV2FPT0WU
SF295NH3MUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIL4XWFKSzVyPUKuN|E2OjRizszNMn3tV2FPT0WU
D-502MGMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorYTWM2OD1{LkOyOFYyKM7:TR?=M1jEXHNCVkeHUh?=
HCC2157NVfVcYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rjNGlEPTB;Mj6zNlkzPyEQvF2=NGC1e2xUSU6JRWK=
D-283MEDNWHrU3EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2SzeWlEPTB;Mj6zOVkzPiEQvF2=MV3TRW5ITVJ?
SNU-423MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\mXVFKSzVyPUKuOFAyPzFizszNNIPBTmRUSU6JRWK=
SK-LU-1NHW3XmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjsOoVKSzVyPUKuOFQ2QDZizszNMnW4V2FPT0WU
22RV1NGTsZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT1WolKSzVyPUKuOFU3OTdizszNNIXJTIZUSU6JRWK=
SW1088NW\FV5RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHGTWM2OD1{LkS5NlE{KM7:TR?=NHGxd29USU6JRWK=
HT-3NFTidoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PKPGlEPTB;Mj60PVI2QSEQvF2=NEnpR2lUSU6JRWK=
NCI-H1666MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJwNUGxNFQh|ryPM1uyZ3NCVkeHUh?=
EM-2M1qzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHRNG5KSzVyPUKuOVEyPjlizszNMXzTRW5ITVJ?
SNU-449MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mme4TWM2OD1{LkW3NFE1KM7:TR?=M4[0c3NCVkeHUh?=
786-0MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJwNUmyN|gh|ryPM3GxTXNCVkeHUh?=
SKG-IIIaM3zQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;QW4RKSzVyPUKuOlU6OzlizszNNInuVJlUSU6JRWK=
MEL-HOMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLPTWM2OD1{Lk[3OlM1KM7:TR?=NIX6O2xUSU6JRWK=
LCLC-97TM1NU\tUZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;TOpE5UUN3ME2yMlY6OjZ5IN88US=>MojZV2FPT0WU
MKN7Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTJwN{C3OVQh|ryPMYHTRW5ITVJ?
5637NVn6UlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH6yTY9KSzVyPUKuO|ExOzVizszNMVHTRW5ITVJ?
HOP-92M{H1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInFZ5RKSzVyPUKuO|Q4OTdizszNMoGwV2FPT0WU
MDA-MB-157NFHzTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTJwOEKwNlMh|ryPM3fxUnNCVkeHUh?=
NB12M{KzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTJwOES5NVQh|ryPMojmV2FPT0WU
DMS-273NFzmcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2xOHVVUUN3ME2yMlg3PDdizszNNFvrSm1USU6JRWK=
HCC70NFXMbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJwOE[1PFkh|ryPMorHV2FPT0WU
YKG-1M2fUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33IeGlEPTB;Mz6wN|c5PyEQvF2=MYTTRW5ITVJ?
NCI-H28MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XjTmlEPTB;Mz6wOVI6OSEQvF2=NHvEfnFUSU6JRWK=
HNMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnziTWM2OD1|LkC2OlM3KM7:TR?=MUXTRW5ITVJ?
HT-1080MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrjVItKSzVyPUOuNFg3ODZizszNMoO1V2FPT0WU
HPAF-IINFvVO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnLT3A5UUN3ME2zMlExODZ6IN88US=>MlTOV2FPT0WU
U-2-OSNX3tfYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fOUmlEPTB;Mz6xN|c5OiEQvF2=NULEfHJKW0GQR1XS
SNU-387MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XlfWlEPTB;Mz6xOlM3PCEQvF2=MVLTRW5ITVJ?
BeckerMkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LOSGlEPTB;Mz6xOlgxQCEQvF2=M3juS3NCVkeHUh?=
BHYNFz2U4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\wNm5pUUN3ME2zMlI2PTdzIN88US=>MVnTRW5ITVJ?
HTC-C3MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXLeWhTUUN3ME2zMlI6OzV{IN88US=>NWL6XY51W0GQR1XS
M14NFHNbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf0TWM2OD1|LkOwOlY{KM7:TR?=NYjt[otrW0GQR1XS
COR-L23MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTNwM{eyO|kh|ryPNEnROVdUSU6JRWK=
C32MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPacm5mUUN3ME2zMlQyPTB6IN88US=>NIL3b4NUSU6JRWK=
MewoM3;ZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjJO2JKSzVyPUOuOFIyQDJizszNMV\TRW5ITVJ?
TE-8MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDQ[IVKSzVyPUOuOFgzPTlizszNNH;pNG5USU6JRWK=
RPMI-2650NWfWTXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTNwNkC2N|ch|ryPNIjOW4tUSU6JRWK=
AGSM4C5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK3PIZmUUN3ME2zMlYzPDZ2IN88US=>NWnUZodHW0GQR1XS
MZ2-MELMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrPTWM2OD1|Lk[2NVM5KM7:TR?=NWjkfWlbW0GQR1XS
Calu-3MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTwTWM2OD1|LkexNlg4KM7:TR?=NHz4NXlUSU6JRWK=
SJSA-1M1q2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrKTWM2OD1|LkexN|E2KM7:TR?=NWXTN3BZW0GQR1XS
SW962M4fMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlK0TWM2OD1|LkeyOlM3KM7:TR?=Mni5V2FPT0WU
PC-14NFXqbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHoNoVKSzVyPUOuO|MzOjJizszNMnLuV2FPT0WU
SW1573NELOSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETxTY1KSzVyPUOuO|U{PDhizszNM{LkNnNCVkeHUh?=
769-PM{\ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLJTWM2OD1|LkiyO|Q{KM7:TR?=MXzTRW5ITVJ?
KNS-62NEjzb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;ob4Q4UUN3ME2zMlkzOzN6IN88US=>NUHKe3Q4W0GQR1XS
NCI-H747NIL6U5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmG4TWM2OD12LkC1OlM5KM7:TR?=NHn2[mxUSU6JRWK=
LN-405M13kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnP3TWM2OD12LkG1O|I5KM7:TR?=NXm1XphzW0GQR1XS
OVCAR-8MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTRwMkK1OFMh|ryPMYrTRW5ITVJ?
DMS-114MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGW1bItKSzVyPUSuNlM5QTFizszNM1nldnNCVkeHUh?=
NCI-H2126MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1G4UWlEPTB;ND6yOFU2QCEQvF2=M2H5OXNCVkeHUh?=
TCCSUPMl3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PJfGlEPTB;ND6yOFc5QCEQvF2=M{\OcnNCVkeHUh?=
SK-N-FIMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUf4eGlyUUN3ME20MlI2OzN{IN88US=>NVzDZXpSW0GQR1XS
HCE-4MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjmTWM2OD12LkK3NVk4KM7:TR?=M1HTS3NCVkeHUh?=
DK-MGM4Th[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTRwM{CzPUDPxE1?Mk\BV2FPT0WU
RO82-W-1M1S5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;TPWlEPTB;ND6zNlU5PCEQvF2=MnvsV2FPT0WU
A2780Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTRwM{[2PFIh|ryPM{TLOHNCVkeHUh?=
ETK-1MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTzdnlsUUN3ME20MlM4ODV{IN88US=>M3f1S3NCVkeHUh?=
FADUNF7MVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETSNWZKSzVyPUSuN|c1PjdizszNNXnXOlBZW0GQR1XS
CAL-12TM2D6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnNUXpKSzVyPUSuOFE1OTNizszNNGfrR4tUSU6JRWK=
647-VMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHtTWM2OD12LkS0NFIzKM7:TR?=NVPlfHd4W0GQR1XS
TGBC1TKBNFXLUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTRwNEWxNVMh|ryPNGfGPJVUSU6JRWK=
LU-99ANWLvS4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTRwNE[wOkDPxE1?NF\LeFBUSU6JRWK=
CAL-33MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTRwNUK0OVYh|ryPNHjlVIRUSU6JRWK=
LU-134-ANIGzXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj1eHVuUUN3ME20MlUzPzR3IN88US=>NF;m[GxUSU6JRWK=
NCI-H1355M2DPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTRwNUWxOFYh|ryPNHH2N49USU6JRWK=
RPMI-7951MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGX0TW1KSzVyPUSuOVcxODJizszNM{e5VnNCVkeHUh?=
TE-1NHLFWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzNTWM2OD12Lk[2NVQ{KM7:TR?=NEm1flRUSU6JRWK=
OE33MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HrVGlEPTB;ND63NFUyOSEQvF2=MXvTRW5ITVJ?
CAL-51MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPGS5VbUUN3ME20MlcyODh{IN88US=>NX\vWGsxW0GQR1XS
SW1783MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoC5TWM2OD12Lke1N|A5KM7:TR?=NFjw[45USU6JRWK=
BT-474NF;0e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTRwN{[zPFQh|ryPM360THNCVkeHUh?=
KYSE-520M4O2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\0TWM2OD12Lki3N|kzKM7:TR?=NEe4ZW9USU6JRWK=
8-MG-BAM{LyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrQTWM2OD12Lki4OVU4KM7:TR?=NX7VS3RHW0GQR1XS
IA-LMM4L2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTYTWM2OD12Lkm5OFM2KM7:TR?=MmPkV2FPT0WU
SW954NUC1WWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXjTWM2OD12Lkm5OFQ{KM7:TR?=MlzOV2FPT0WU
RPMI-8226Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVi3XWhkUUN3ME21MlA2PDZzIN88US=>NH31UmhUSU6JRWK=
MKN1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYH0UnhnUUN3ME21MlA4QTJ5IN88US=>M4jjfXNCVkeHUh?=
A375NXfrR49[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTVwMEmyOVYh|ryPNEXnd2hUSU6JRWK=
8305CMnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HRNmlEPTB;NT6wPVg5PyEQvF2=NH\OUZFUSU6JRWK=
CAL-62MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXrelVKSzVyPUWuNVgzPTlizszNM{f0THNCVkeHUh?=
NB10M{\jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnEbHZLUUN3ME21MlIzPzR2IN88US=>MYfTRW5ITVJ?
OC-314NWPVWYVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1K3bmlEPTB;NT6zO|Q1PCEQvF2=M4nONXNCVkeHUh?=
PSN1M{jzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m5N2lEPTB;NT6zPFI5PiEQvF2=MVPTRW5ITVJ?
GR-STM{TsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnq5TWM2OD13LkO4N|IzKM7:TR?=MkXLV2FPT0WU
P12-ICHIKAWANG[0WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fWSmlEPTB;NT60NFEh|ryPM2TiWnNCVkeHUh?=
NCI-H1092MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTVwNEGxOFgh|ryPNYTkSGxTW0GQR1XS
SCC-4MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTVwNEGzOVUh|ryPNXLhPGNyW0GQR1XS
TE-6MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoD2TWM2OD13LkSxPFE3KM7:TR?=M2jLSnNCVkeHUh?=
DOHH-2NGPFfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjHZXNKSzVyPUWuOFIzPDhizszNMUnTRW5ITVJ?
SW684M4PpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTVwNk[zPFUh|ryPNW\INVdvW0GQR1XS
CP50-MEL-BNIKyU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\DRmlEPTB;NT62PFY5PCEQvF2=M1;lZ3NCVkeHUh?=
UM-UC-3M3SwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3KTWM2OD13LkeyNlMyKM7:TR?=NWrNT4xkW0GQR1XS
LC-2-adM{DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTVwN{iyOVEh|ryPNGDPNlNUSU6JRWK=
PC-3M2XpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTVwOUG2NVUh|ryPMlzEV2FPT0WU
CANMnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[5[pNoUUN3ME21MlkzQDJizszNMUHTRW5ITVJ?
ESS-1M{OwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fpWWlEPTB;NT65O|g3QSEQvF2=MUPTRW5ITVJ?
ATN-1M{P3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7STWM2OD14LkC1OVY5KM7:TR?=M160WnNCVkeHUh?=
BxPC-3NHTBZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DxSmlEPTB;Nj6wPFIyQSEQvF2=NGDGXVRUSU6JRWK=
KYSE-150NGXmNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;hSokxUUN3ME22MlEzPDd4IN88US=>MX7TRW5ITVJ?
RPMI-8866M{fKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7kTWM2OD14LkG5NVY{KM7:TR?=M1;k[3NCVkeHUh?=
SW780M1LzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX5fW97UUN3ME22MlIxPDJizszNM{W1XHNCVkeHUh?=
A388NILwOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlP1TWM2OD14LkKzNVE2KM7:TR?=M4nBdnNCVkeHUh?=
NCI-H1437MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInH[npKSzVyPU[uNlQxPzNizszNNVXSbnplW0GQR1XS
NCI-H1755Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXsd4ZKSzVyPU[uN|Y3OTJizszNNV7UbolsW0GQR1XS
LS-123NVjYS45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXXfFlZUUN3ME22MlQxPTJzIN88US=>M4PreXNCVkeHUh?=
CaR-1NYLOdnl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{e1Z2lEPTB;Nj60OlM4OyEQvF2=NXzWdHg3W0GQR1XS
RT-112NVT5ZZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\6[FVKSzVyPU[uOlA{OzhizszNNFLC[YZUSU6JRWK=
CGTMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\SZpBKSzVyPU[uO|M3QDFizszNNXTD[G9nW0GQR1XS
SW626Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTZwN{O5OFYh|ryPNFfiWXNUSU6JRWK=
AsPC-1NV;RcW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHDTVZKSzVyPU[uO|Q2ODdizszNMo\ZV2FPT0WU
SBC-5NWq5UmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvnVFJzUUN3ME22Mlk4Ojl5IN88US=>NWnjS4NbW0GQR1XS
SF539M{P6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTnTWM2OD14Lkm5N|M{KM7:TR?=MVnTRW5ITVJ?
TI-73M1v0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;DemlEPTB;Nz6wOlI5PSEQvF2=NELwU5lUSU6JRWK=
MHH-ES-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlW2TWM2OD15LkC3O|YzKM7:TR?=Ml\kV2FPT0WU
KYSE-510MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWO5eGh5UUN3ME23MlA5PDN{IN88US=>MVTTRW5ITVJ?
EW-1NFjifFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXDTWM2OD15LkO2PVk3KM7:TR?=MV3TRW5ITVJ?
SK-OV-3MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITlR3pKSzVyPUeuN|k1OzJizszNNXTsZm5ZW0GQR1XS
MC-IXCMl\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTdwNEG5O|Ih|ryPMYLTRW5ITVJ?
HSC-2MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWOwb2J1UUN3ME23MlQzPzB3IN88US=>NHrseXpUSU6JRWK=
NCI-H2342NV\VVYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HNXmlEPTB;Nz61NVQ6KM7:TR?=NF;iTo5USU6JRWK=
NCI-H1792Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH4U49rUUN3ME23MlUyPzFzIN88US=>NE[3VHFUSU6JRWK=
HT-1376MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjEO4g{UUN3ME23Mlg4Pzd6IN88US=>Mn\LV2FPT0WU
EW-13Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjBc4hnUUN3ME23Mlg6QTd5IN88US=>NHPVe|JUSU6JRWK=
no-11M1nRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTdwOUCxO|Qh|ryPMUfTRW5ITVJ?
DaoyMnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHJTWM2OD15Lkm0N|IyKM7:TR?=NUi5dm9GW0GQR1XS
COLO-800NUHPWWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXTTVF4UUN3ME24MlA1OTZ{IN88US=>MVzTRW5ITVJ?
GB-1NX\NepgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHGxdlhKSzVyPUiuNFY2PjVizszNMYLTRW5ITVJ?
SJRH30MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRThwMUW4O|gh|ryPMne5V2FPT0WU
NCI-H2291NETYTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfMTWM2OD16LkK5NVg4KM7:TR?=M{D5[nNCVkeHUh?=
J82NFLtVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRThwMkm0PVEh|ryPMWjTRW5ITVJ?
NCI-H596MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPjNm13UUN3ME24MlMyPDV|IN88US=>M{XSenNCVkeHUh?=
RERF-LC-MSMn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVKwbWN5UUN3ME24MlM1QDV4IN88US=>MoXtV2FPT0WU
RH-18MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRThwM{WwOFYh|ryPMVnTRW5ITVJ?
SW48MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLTTWM2OD16LkW5OFU{KM7:TR?=NFrDWm9USU6JRWK=
RDMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfBbGlGUUN3ME24MlU6OzlzIN88US=>M4n1ZnNCVkeHUh?=
MS-1M{jtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XUdWlEPTB;OD62NVM5PyEQvF2=NV;Ob2FIW0GQR1XS
ES6M4X5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1WwO2lEPTB;OD63N|EyQSEQvF2=M4rHbnNCVkeHUh?=
TE-12MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHH4Sm5KSzVyPUiuO|c2ODVizszNNHfQfphUSU6JRWK=
DBTRG-05MGNELqemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnv5TWM2OD16LkmxNlE4KM7:TR?=NX;FUoI1W0GQR1XS
KINGS-1Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjxToFKSzVyPUiuPVI6OzhizszNMYLTRW5ITVJ?
HLEMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonFTWM2OD16LkmzO|g2KM7:TR?=MWPTRW5ITVJ?
MHH-NB-11MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTlwMEG4N|kh|ryPMWPTRW5ITVJ?
U-87-MGMlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLKeY9KSzVyPUmuNlQ{OjFizszNM33DNHNCVkeHUh?=
MN-60NEmyfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPXbW5lUUN3ME25MlI1PTR{IN88US=>NYH1fYRtW0GQR1XS
SASMnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXS4emYzUUN3ME25MlI2PThzIN88US=>M1Xl[XNCVkeHUh?=
NCI-H446MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTlwM{[xJO69VQ>?NXvxOlFxW0GQR1XS
C-33-AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3K4bWlEPTB;OT60N|k5QCEQvF2=MmjYV2FPT0WU
RXF393NHnGNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTlwNEewNFIh|ryPNV\wSG13W0GQR1XS
CGTH-W-1NGC1XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrVbopXUUN3ME25MlQ6Ozh2IN88US=>NXzYVYNuW0GQR1XS
RCM-1NI\QbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTlwNkO4NFEh|ryPMWHTRW5ITVJ?
SN12CNWfJU3l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPhU2JiUUN3ME25MlY2OzN6IN88US=>NIT6[JdUSU6JRWK=
KLEM3njc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTlwN{CwNFkh|ryPNV\rboFCW0GQR1XS
EFO-21MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TDOGlEPTB;OT63O|M5OiEQvF2=NFfsXoFUSU6JRWK=
KYSE-70M2\qUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTlwOEiwNVEh|ryPMoe5V2FPT0WU
D-247MGMkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTFyLkC1Olgh|ryPMYjTRW5ITVJ?
MPP-89NIfGXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLwOYhQUUN3ME2xNE4xQTR4IN88US=>MoDyV2FPT0WU
RVH-421MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXwTWM2OD1zMD6xOVA2KM7:TR?=NH3ZbWlUSU6JRWK=
NCI-H460NVftcnI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmG4TWM2OD1zMD6yPFA3KM7:TR?=NIPw[IlUSU6JRWK=
NOMO-1NXj1bmNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPzVmFKSzVyPUGwMlM2OzJizszNM{XYcnNCVkeHUh?=
DELNHqwUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYH0S4tMUUN3ME2xNE4{Pzl2IN88US=>MlXZV2FPT0WU
HT55Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTFyLk[yNFUh|ryPNFqzd5ZUSU6JRWK=
MC116NEfmOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPYcHRKSzVyPUGwMlY3PTVizszNM3\kRnNCVkeHUh?=
BB30-HNCNIfNeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnywTWM2OD1zMD62Olkh|ryPMWLTRW5ITVJ?
DJM-1NEPzUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzCTWM2OD1zMD62PVQ6KM7:TR?=MUTTRW5ITVJ?
ZR-75-30M4nGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTFyLkm0OFEh|ryPNXu5Z4NiW0GQR1XS
U-118-MGNVe1ZpZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n2U2lEPTB;MUCuPVg6PiEQvF2=NFfmfnBUSU6JRWK=
MSTO-211HMke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\BWo1WUUN3ME2xNU4xPzF4IN88US=>M4PIdnNCVkeHUh?=
SW837MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfKOW1KSzVyPUGxMlA6PDlizszNNUnGXnVpW0GQR1XS
HuCCT1MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHi1N4xKSzVyPUGxMlEzQDFizszNNInxXWVUSU6JRWK=
RCC10RGBM1WyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFzLkGzOUDPxE1?MYLTRW5ITVJ?
NMC-G1NX;ZUVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;BZW5XUUN3ME2xNU4yPDl|IN88US=>MUTTRW5ITVJ?
NCI-H650MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XUU2lEPTB;MUGuN|c6PCEQvF2=MXrTRW5ITVJ?
HEC-1M1vRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInZ[o9KSzVyPUGxMlQ{OjhizszNMW\TRW5ITVJ?
DU-4475MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnH1TWM2OD1zMT63N|k{KM7:TR?=M{nqTHNCVkeHUh?=
DSH1M1O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jZXmlEPTB;MUGuO|YxPiEQvF2=NFnBdnpUSU6JRWK=
HCC1569NXnPcWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFzLke2O|gh|ryPMYrTRW5ITVJ?
HCC1187NETPe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFzLki1PFgh|ryPMmLtV2FPT0WU
EW-11MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvVN5RiUUN3ME2xNU46PDd2IN88US=>Mom5V2FPT0WU
LB2518-MELM4nC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XRTWlEPTB;MUKuNFU6KM7:TR?=MXnTRW5ITVJ?
KALS-1MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjneIZKSzVyPUGyMlg2PTNizszNNULLSldDW0GQR1XS
8505CMnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTYeY05UUN3ME2xNk45QDVizszNNV\Hc5FGW0GQR1XS
SK-N-DZMkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jTZmlEPTB;MUOuNFQ2OyEQvF2=NV;CXppjW0GQR1XS
CHP-134M1\aVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrQTWM2OD1zMz6xNVU5KM7:TR?=MW\TRW5ITVJ?
HCE-TMkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHyz[JpKSzVyPUGzMlI{PjRizszNNXnzO3U3W0GQR1XS
LB-831-BLCMnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrtbJFtUUN3ME2xN{43OjR4IN88US=>M1zteXNCVkeHUh?=
OVCAR-4NU\HU2tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\pOXdKSzVyPUGzMlY2OjRizszNM1fyVXNCVkeHUh?=
SW756M1;s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr2cXZKSzVyPUGzMlczPDZizszNNIDtWYtUSU6JRWK=
OCUB-MMo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M171OWlEPTB;MUOuPFE2PiEQvF2=MYHTRW5ITVJ?
SW982M3rlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jEPWlEPTB;MUOuPFI4PiEQvF2=NULtVW1lW0GQR1XS
DBNEju[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPUTWM2OD1zMz64N|g1KM7:TR?=MofwV2FPT0WU
H-EMC-SSM4X2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnubY9KSzVyPUGzMlkyOzlizszNNYfhSYZDW0GQR1XS
VMRC-RCZMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInObHpKSzVyPUG0MlAxOTVizszNMlTqV2FPT0WU
CAKI-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTF2LkCxN|Ih|ryPNWrnVWtYW0GQR1XS
GI-1NUjMO5dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrKOoxKSzVyPUG0MlA3PThizszNNGfu[m5USU6JRWK=
Ca9-22NUHDeGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\1UY5KSzVyPUG0MlYxPTRizszNNV62OW5KW0GQR1XS
TE-5NGTOZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DTO2lEPTB;MUSuO|IxQCEQvF2=MUTTRW5ITVJ?
EFO-27Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF2Lke2NlIh|ryPNVXC[lBiW0GQR1XS
CAL-72M3TyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrNemFKSzVyPUG0Mlc4QDNizszNMnXNV2FPT0WU
GP5dM3PORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzFTWM2OD1zNT6wOFc1KM7:TR?=NV\sXYc3W0GQR1XS
CAS-1NX3WUpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13nTGlEPTB;MUWuNFY3KM7:TR?=NWnIendyW0GQR1XS
A2058MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXyTHpKSzVyPUG1MlU3OzhizszNMWHTRW5ITVJ?
PANC-08-13NFy3RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrkdWJ5UUN3ME2xOU43QDV7IN88US=>M3ztW3NCVkeHUh?=
Detroit562MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF3LkmxN|kh|ryPMYHTRW5ITVJ?
PANC-10-05MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\oZ2lEPTB;MU[uNFgzOSEQvF2=MVTTRW5ITVJ?
KOSC-2NIjyTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTF4LkGxNlUh|ryPM4LB[XNCVkeHUh?=
GT3TKBMln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF4LkG5PFEh|ryPNXLrNG1NW0GQR1XS
KM-H2M1LkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnKc|BYUUN3ME2xOk4{PjR4IN88US=>NWf4cpJtW0GQR1XS
LB771-HNCMkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\SNmtKSzVyPUG2MlQ1OjJizszNNVyyPWtPW0GQR1XS
SF268Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTF4LkS1NkDPxE1?NIPMPJhUSU6JRWK=
OE19NF7kellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jtemlEPTB;MU[uOVI1KM7:TR?=NFvoV3VUSU6JRWK=
MLMAMljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4j1WWlEPTB;MU[uOVU4OSEQvF2=MXLTRW5ITVJ?
MDA-MB-231NUS3eFFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HMeWlEPTB;MU[uO|E{PiEQvF2=NEXMU3dUSU6JRWK=
TGWNXPscpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF4LkixNFIh|ryPMWXTRW5ITVJ?
MDA-MB-453NVu0UFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7lPHdKSzVyPUG3MlAxODNizszNNF\sSGxUSU6JRWK=
SNU-C2BNUL6NVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LyfmlEPTB;MUeuNFI{PyEQvF2=MnnyV2FPT0WU
A427M3jlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF5LkKzN|Qh|ryPNYG3eZE5W0GQR1XS
SK-MEL-2NU\UPJZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fqNGlEPTB;MUeuN|IyOyEQvF2=NHzIUFlUSU6JRWK=
KURAMOCHIM4TxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXrTWM2OD1zNz6zPFk4KM7:TR?=NUTWSHJKW0GQR1XS
IST-MEL1NGPCcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF5LkmxPFIh|ryPM1fiU3NCVkeHUh?=
NCI-H1793NULHcoVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfpTWM2OD1zOD6xOVgyKM7:TR?=NX3oUnV1W0GQR1XS
HCC1395MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;tTWM2OD1zOD61OlEyKM7:TR?=NUHSU2VDW0GQR1XS
NUGC-3MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPHdIlRUUN3ME2xPE43PTh2IN88US=>MoWzV2FPT0WU
BB65-RCCMkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXW[2ZEUUN3ME2xPE43PjlizszNMmDrV2FPT0WU
RMG-IMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\lTWM2OD1zOD63N|gzKM7:TR?=Mn\CV2FPT0WU
LS-513MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVKxb4QyUUN3ME2xPE46OjJ6IN88US=>NUjte4ZHW0GQR1XS
MFM-223NYHsNYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\zRWlEPTB;MUmuNFcyPiEQvF2=NUj2e4pqW0GQR1XS
NCI-H727MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTF7LkOyPVUh|ryPMYfTRW5ITVJ?
KP-4NEmwSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLo[21KSzVyPUG5Mlg2OzFizszNMV7TRW5ITVJ?
NB13Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TVdGlEPTB;MUmuPFg{QSEQvF2=NGXZXZVUSU6JRWK=
UACC-893MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF7Lkm3OVch|ryPMU\TRW5ITVJ?
HT-1197NUL1VFZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGxUlFKSzVyPUKwMlI6PThizszNMmTrV2FPT0WU
NCI-H2029NF3rS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfkbJNXUUN3ME2yNE4{OjZ4IN88US=>MlO2V2FPT0WU
GI-ME-NNGXqflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTJyLkOzO|Mh|ryPMWfTRW5ITVJ?
OVCAR-3NIr1U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PNemlEPTB;MkCuOVgzOiEQvF2=MXXTRW5ITVJ?
HD-MY-ZNYDSRY9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET4bIlKSzVyPUKxMlM3QTZizszNMl:wV2FPT0WU
NTERA-S-cl-D1NXflS|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJzLk[3NlIh|ryPNIj2PHhUSU6JRWK=
SCHNV\Zc3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTJ{LkS5OkDPxE1?MVLTRW5ITVJ?
KARPAS-299NGLxXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWWzWGdmUUN3ME2yN{4{QDh5IN88US=>M2Lh[3NCVkeHUh?=
NCI-H1650M1zwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHyxWFdKSzVyPUKzMlkzPDFizszNNYn4cIxoW0GQR1XS
ACHNNIPNWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkn4TWM2OD1{ND60OlU3KM7:TR?=M3\VPHNCVkeHUh?=
M059JMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TSe2lEPTB;MkSuOVY{PCEQvF2=MlfUV2FPT0WU
AM-38Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJ3LkS4NUDPxE1?NYO1T3lXW0GQR1XS
KG-1M4TKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7rPWZKSzVyPUK1MlU1QTRizszNNIr1XYNUSU6JRWK=
COLO-824MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJ3LkW1PVkh|ryPMnn5V2FPT0WU
NCI-H1155NUjpeJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLjO|hrUUN3ME2yOU42QDR5IN88US=>NVTxV|BpW0GQR1XS
NCI-H441MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ3Lke0OlUh|ryPMVPTRW5ITVJ?
J-RT3-T3-5NIW2NpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkToTWM2OD1{Nj6zNFI4KM7:TR?=M3rvS3NCVkeHUh?=
JEG-3MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fYXGlEPTB;Mk[uOlgxPSEQvF2=M2jEWHNCVkeHUh?=
RKONHPKO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fC[GlEPTB;Mk[uO|Y{OiEQvF2=NVHJV49oW0GQR1XS
CAL-85-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorwTWM2OD1{Nz6yNVE5KM7:TR?=MYPTRW5ITVJ?
CAL-120NU\G[2t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJ5Lk[5NVQh|ryPNIDBNXNUSU6JRWK=
NCI-H2452Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlr2TWM2OD1{Nz63O|E3KM7:TR?=M4\YSXNCVkeHUh?=
NCI-H1395M3\qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJ5Lke4N|Mh|ryPNF\aNm1USU6JRWK=
KYSE-450M{HkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ5Lkm4OlIh|ryPNX6yW|Z7W0GQR1XS
S-117MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\CTWM2OD1{OT6zPFU4KM7:TR?=MV;TRW5ITVJ?
SW13NHTIOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q2UGlEPTB;MkmuPFUyQSEQvF2=MnzjV2FPT0WU
ES3NEi2WIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfEOVZKSzVyPUOwMlM4OzNizszNNImzXIpUSU6JRWK=
HCT-116MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHCTWM2OD1|MD61OVU1KM7:TR?=NEnvbIJUSU6JRWK=
NCI-H1693MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\0eod[UUN3ME2zNE42QTR{IN88US=>NHfoe4tUSU6JRWK=
VM-CUB-1M13kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\iS|NMUUN3ME2zNE43PDF|IN88US=>NEfUfVNUSU6JRWK=
NCI-H2170Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3rW48{UUN3ME2zNU42Pzh2IN88US=>MWHTRW5ITVJ?
ALL-POMmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHtPGJKSzVyPUOxMlg1OjhizszNNYPTeXN[W0GQR1XS
NCI-H661MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LKO2lEPTB;M{KuNFYzOyEQvF2=M{nW[3NCVkeHUh?=
NCI-H2347NWj5SVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTN{LkS4N|ch|ryPMX\TRW5ITVJ?
FTC-133Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHnTWM2OD1|Mj63NFYh|ryPNFLueGlUSU6JRWK=
COLO-829MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHsOYxKSzVyPUOzMlM1PjdizszNNHjEZXBUSU6JRWK=
GOTONGHOUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnz1TWM2OD1|Mz61NlU5KM7:TR?=M4XLTXNCVkeHUh?=
YAPCNGHZNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTN|LkixOVkh|ryPMU\TRW5ITVJ?
LCLC-103HNFX6doJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\ETWM2OD1|ND6xOlI1KM7:TR?=NF;V[o1USU6JRWK=
SiHaMnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLkXnJKSzVyPUO0MlM5OTdizszNMlGyV2FPT0WU
LK-2NHyyc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jiPGlEPTB;M{SuOVcxQCEQvF2=MV7TRW5ITVJ?
KP-N-YSMk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3y4UmlEPTB;M{SuO|IxOiEQvF2=MorUV2FPT0WU
NCI-SNU-1M3LkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvIfnNKSzVyPUO1MlE4QSEQvF2=NVq4O25uW0GQR1XS
KNS-81-FDMmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XPU2lEPTB;M{WuOlY{KM7:TR?=NV;KOlVxW0GQR1XS
SCC-9M1O5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjLTWM2OD1|Nj63NVQ3KM7:TR?=MVPTRW5ITVJ?
SH-4NWPBWJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LaSmlEPTB;M{[uO|Mh|ryPNWDTbHl4W0GQR1XS
HCC-1954MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLXTWM2OD1|Nz6yO|I6KM7:TR?=MUHTRW5ITVJ?
BALL-1NIGyR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mof6TWM2OD1|Nz61N|E3KM7:TR?=M4LRVHNCVkeHUh?=
BE-13NVO0bWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTWSnd5UUN3ME2zO{44ODF6IN88US=>NUTneHVTW0GQR1XS
COLO-678NW\OSGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTN5Lkm0N|ch|ryPNGi4NpVUSU6JRWK=
SK-MEL-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37m[mlEPTB;M{iuNlM6PyEQvF2=M13vR3NCVkeHUh?=
OAW-28M4XoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\xTWM2OD1|OD62N|kh|ryPMmjyV2FPT0WU
CAMA-1NU\nWHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmW3TWM2OD1|OD65OlkyKM7:TR?=M{HiOXNCVkeHUh?=
C2BBe1NGj5VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ntNmlEPTB;M{muPFE5KM7:TR?=NFf2S4RUSU6JRWK=
A3-KAWNYjLSHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTRyLkO2OlEh|ryPNGT3PY5USU6JRWK=
SK-MEL-24MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPM[GhUUUN3ME20NE42QTNzIN88US=>NX6zO2dLW0GQR1XS
KYSE-140NYDRWm9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrIVnNCUUN3ME20NE44OTZ3IN88US=>MYXTRW5ITVJ?
MOLT-16M1n5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPmTWM2OD12MT6xOVM3KM7:TR?=MYPTRW5ITVJ?
CFPAC-1M{LEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnqyTWM2OD12Mj61NlEyKM7:TR?=MXnTRW5ITVJ?
NB14NXHJ[odVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XiS2lEPTB;NEKuO|AzPyEQvF2=M1HXbnNCVkeHUh?=
COLO-792M4Xx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17QVmlEPTB;NEKuPFk3OSEQvF2=NVHMTWRIW0GQR1XS
RH-1NXHTbVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\ZTY5KSzVyPUSzMlQ5OzZizszNNXz0dmpDW0GQR1XS
NCI-H522MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoO3TWM2OD12ND6zOVY5KM7:TR?=Mkm3V2FPT0WU
Ca-SkiMmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnTcnZMUUN3ME20OE45OTF2IN88US=>MV;TRW5ITVJ?
KGNNFWzTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTR6LkOwOlMh|ryPNGKzVlVUSU6JRWK=
UACC-62NWCyXIV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LNPGlEPTB;NEiuOFA4OiEQvF2=M2S1[nNCVkeHUh?=
NCI-H358NH7rRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnSXmJZUUN3ME20PU4{ODF6IN88US=>Mle0V2FPT0WU
LS-411NNFHvclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXW5RXlEUUN3ME20PU4{OTF6IN88US=>Mn25V2FPT0WU
IST-MES1NF3ObJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTR7LkW2NlUh|ryPNUGydItYW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. [1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. [2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Scintillation proximity assay Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl2, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-33P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.

Cell Assay: [2]

Cell lines SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 48 and 72 hours
Method Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISAplus assay are used to detect caspase 3/7 activity, and apoptosis, respectively.

Animal Study: [2]

Animal Models NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdcscid mice implanted subcutaneously with BT474-M1 cells
Formulation Dissolved in 10% DMSO, 5% Tween 20, 85% water
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Folkes AJ, et al. J Med Chem, 2008, 51(18), 5522-5532.

[2] Junttila TT, et al. Cancer Cell, 2009, 15(5), 429-440.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02092831 Completed Healthy Volunteer Genentech, Inc. April 2014 Phase 1
NCT01740336 Active, not recruiting Breast Cancer Genentech, Inc. February 2013 Phase 2
NCT01493843 Completed Non-Squamous Non-Small Cell Lung Cancer Genentech, Inc. January 2012 Phase 2
NCT01437566 Completed Breast Cancer Genentech, Inc. October 2011 Phase 2
NCT01474668 Completed Healthy Volunteer Genentech, Inc. October 2011 Phase 1

view more

Chemical Information

Download Pictilisib (GDC-0941) SDF
Molecular Weight (MW) 513.64
Formula

C23H27N7O3S2

CAS No. 957054-30-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms RG7321
Solubility (25°C) * In vitro DMSO 44 mg/mL (85.66 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidine

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PI3K Products

  • GDC-0032

    GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Recently Viewed Items

Tags: buy Pictilisib (GDC-0941) | Pictilisib (GDC-0941) supplier | purchase Pictilisib (GDC-0941) | Pictilisib (GDC-0941) cost | Pictilisib (GDC-0941) manufacturer | order Pictilisib (GDC-0941) | Pictilisib (GDC-0941) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us